缺血性脑卒中静脉溶栓治疗研究进展
Research Progress on Intravenous Thrombolytic Therapy for Ischemic Stroke
摘要: 卒中是一种有着高致残率、高复发率、高死亡率的常见疾病，静脉溶栓是急性缺血性卒中患者目前最容易获得和最有效的再灌注疗法，尽快开通血管、恢复血流、挽救缺血半暗带，尽可能地减少缺血性卒中的致残率和死亡率，静脉溶栓治疗提高了良好功能结局的比例，且出血并发症的风险极低。随着新型溶栓药物的出现，治疗从时间窗逐渐向组织窗过渡，在特殊患者是否溶栓中权衡利弊，因此本论文对急性缺血性卒中的应用及最新进展进行综述讨论。
Abstract: Stroke is a common disease characterized by high disability, recurrence, and mortality rates. Intravenous thrombolysis (IVT) is currently the most accessible and effective reperfusion therapy for acute ischemic stroke (AIS). It aims to rapidly restore blood flow, salvage the ischemic penumbra, and minimize disability and mortality. IVT improves the likelihood of favorable functional outcomes with a low risk of hemorrhagic complications. With the emergence of novel thrombolytic agents, the treatment paradigm is gradually shifting from a strict time window to a tissue window approach, requiring careful risk-benefit assessment in specific patient populations. This review discusses the application and latest advances in IVT for AIS.
文章引用：刘素妮, 易黎. 缺血性脑卒中静脉溶栓治疗研究进展[J]. 临床医学进展, 2025, 15(5): 1433-1439. https://doi.org/10.12677/acm.2025.1551511

参考文献

[1] Stinear, C.M., Lang, C.E., Zeiler, S. and Byblow, W.D. (2020) Advances and Challenges in Stroke Rehabilitation. The Lancet Neurology, 19, 348-360. [Google Scholar] [CrossRef] [PubMed]
[2] Tadi, P. and Lui, F. (2023) Acute Stroke. StatPearls Publishing.
[3] Feske, S.K. (2021) Ischemic Stroke. The American Journal of Medicine, 134, 1457-1464. [Google Scholar] [CrossRef] [PubMed]
[4] Salaudeen, M.A., Allan, S. and Pinteaux, E. (2024) Hypoxia and Interleukin-1-Primed Mesenchymal Stem/Stromal Cells as Novel Therapy for Stroke. Human Cell, 37, 154-166. [Google Scholar] [CrossRef] [PubMed]
[5] The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue Plasminogen Activator for Acute Ischemic Stroke. The New England Journal of Medicine, 333, 1581-1588. [Google Scholar] [CrossRef] 
[6] 李光硕, 赵性泉.《中国急性缺血性卒中诊治指南2023》解读[J]. 中国卒中杂志, 2024, 19(8): 956-961.
[7] 黄文立, 宫淑杰, 吴志生, 等. 急性脑梗死合并前循环大血管闭塞患者桥接治疗和机械取栓临床的效果分析[J].中风与神经疾病杂志, 2019, 36(2): 147-149.
[8] 郑斯莉, 缪朝玉. 组织型纤溶酶原激活剂治疗急性缺血性脑卒中的作用机制及临床应用[J]. 中国药理学与毒理学杂志, 2018, 32(8): 595-606.
[9] Al‐Ajlan, F.S., Alkhiri, A., Alamri, A.F., Alghamdi, B.A., Almaghrabi, A.A., Alharbi, A.R., et al. (2024) Golden Hour Intravenous Thrombolysis for Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis. Annals of Neurology, 96, 582-590. [Google Scholar] [CrossRef] [PubMed]
[10] Grotta, J.C. (2014) tPA for Stroke: Important Progress in Achieving Faster Treatment. JAMA, 311, 1615-1617. [Google Scholar] [CrossRef] [PubMed]
[11] Kim, H., Kim, J., Lee, J.S., Kim, B.J., Park, J., Kang, K., et al. (2021) Golden Hour Thrombolysis in Acute Ischemic Stroke: The Changing Pattern in South Korea. Journal of Stroke, 23, 135-138. [Google Scholar] [CrossRef] [PubMed]
[12] Tsivgoulis, G., Katsanos, A.H., Kadlecová, P., Czlonkowska, A., Kobayashi, A., Brozman, M., et al. (2017) Intravenous Thrombolysis for Ischemic Stroke in the Golden Hour: Propensity-Matched Analysis from the SITS-EAST Registry. Journal of Neurology, 264, 912-920. [Google Scholar] [CrossRef] [PubMed]
[13] Keen, C.E. (2021) Mobile Stroke Units: When Emergency Medicine Hits the Road.
https://healthcare-in-europe.com/
[14] Fassbender, K., Merzou, F., Lesmeister, M., Walter, S., Grunwald, I.Q., Ragoschke-Schumm, A., et al. (2021) Impact of Mobile Stroke Units. Journal of Neurology, Neurosurgery & Psychiatry, 92, 815-822. [Google Scholar] [CrossRef] [PubMed]
[15] Yperzeele, L., Van Hooff, R., De Smedt, A., Valenzuela Espinoza, A., Van de Casseye, R., Hubloue, I., et al. (2014) Prehospital Stroke Care: Limitations of Current Interventions and Focus on New Developments. Cerebrovascular Diseases, 38, 1-9. [Google Scholar] [CrossRef] [PubMed]
[16] Röhrs, K.J. and Audebert, H. (2024) Pre-Hospital Stroke Care Beyond the MSU. Current Neurology and Neuroscience Reports, 24, 315-322. [Google Scholar] [CrossRef] [PubMed]
[17] Ebinger, M., Kunz, A., Wendt, M., Rozanski, M., Winter, B., Waldschmidt, C., et al. (2015) Effects of Golden Hour Thrombolysis: A Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) Substudy. JAMA Neurology, 72, 25. [Google Scholar] [CrossRef] [PubMed]
[18] Walter, S., Audebert, H.J., Katsanos, A.H., Larsen, K., Sacco, S., Steiner, T., et al. (2022) European Stroke Organisation (ESO) Guidelines on Mobile Stroke Units for Prehospital Stroke Management. European Stroke Journal, 7, XXVII-LIX. [Google Scholar] [CrossRef] [PubMed]
[19] Emberson, J., Lees, K.R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., et al. (2014) Effect of Treatment Delay, Age, and Stroke Severity on the Effects of Intravenous Thrombolysis with Alteplase for Acute Ischaemic Stroke: A Meta-Analysis of Individual Patient Data from Randomised Trials. The Lancet, 384, 1929-1935. [Google Scholar] [CrossRef] [PubMed]
[20] Khaja, A.M. and Grotta, J.C. (2007) Established Treatments for Acute Ischaemic Stroke. The Lancet, 369, 319-330. [Google Scholar] [CrossRef] [PubMed]
[21] Rimmele, D.L. and Thomalla, G. (2014) Wake-Up Stroke: Clinical Characteristics, Imaging Findings, and Treatment Option—An Update. Frontiers in Neurology, 5, Article 35. [Google Scholar] [CrossRef] [PubMed]
[22] Thomalla, G., Rossbach, P., Rosenkranz, M., Siemonsen, S., Krützelmann, A., Fiehler, J., et al. (2009) Negative Fluid‐Attenuated Inversion Recovery Imaging Identifies Acute Ischemic Stroke at 3 Hours or Less. Annals of Neurology, 65, 724-732. [Google Scholar] [CrossRef] [PubMed]
[23] Petkova, M., Rodrigo, S., Lamy, C., Oppenheim, G., Touzé, E., Mas, J., et al. (2010) MR Imaging Helps Predict Time from Symptom Onset in Patients with Acute Stroke: Implications for Patients with Unknown Onset Time. Radiology, 257, 782-792. [Google Scholar] [CrossRef] [PubMed]
[24] Albers, G.W., Marks, M.P., Kemp, S., Christensen, S., Tsai, J.P., Ortega-Gutierrez, S., et al. (2018) Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. New England Journal of Medicine, 378, 708-718. [Google Scholar] [CrossRef] [PubMed]
[25] Chemmanam, T., Campbell, B.C.V., Christensen, S., Nagakane, Y., Desmond, P.M., Bladin, C.F., et al. (2010) Ischemic Diffusion Lesion Reversal Is Uncommon and Rarely Alters Perfusion-Diffusion Mismatch. Neurology, 75, 1040-1047. [Google Scholar] [CrossRef] [PubMed]
[26] Thomalla, G., Simonsen, C.Z., Boutitie, F., Andersen, G., Berthezene, Y., Cheng, B., et al. (2018) MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. New England Journal of Medicine, 379, 611-622. [Google Scholar] [CrossRef] [PubMed]
[27] Logallo, N., Kvistad, C.E., Nacu, A. and Thomassen, L. (2016) Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities. CNS Drugs, 30, 101-108. [Google Scholar] [CrossRef] [PubMed]
[28] Baruah, D.B., Dash, R.N., Chaudhari, M.R. and Kadam, S.S. (2006) Plasminogen Activators: A Comparison. Vascular Pharmacology, 44, 1-9. [Google Scholar] [CrossRef] [PubMed]
[29] Li, G., Wang, C., Wang, S., Xiong, Y. and Zhao, X. (2022) Tenecteplase in Ischemic Stroke: Challenge and Opportunity. Neuropsychiatric Disease and Treatment, 18, 1013-1026. [Google Scholar] [CrossRef] [PubMed]
[30] Keyt, B.A., Paoni, N.F., Refino, C.J., Berleau, L., Nguyen, H., Chow, A., et al. (1994) A Faster-Acting and More Potent Form of Tissue Plasminogen Activator. Proceedings of the National Academy of Sciences, 91, 3670-3674. [Google Scholar] [CrossRef] [PubMed]
[31] Campbell, B.C.V., Mitchell, P.J., Churilov, L., Yassi, N., Kleinig, T.J., Dowling, R.J., et al. (2018) Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. New England Journal of Medicine, 378, 1573-1582. [Google Scholar] [CrossRef] [PubMed]
[32] Campbell, B.C.V., Mitchell, P.J., Kleinig, T.J., Dewey, H.M., Churilov, L., Yassi, N., et al. (2015) Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. New England Journal of Medicine, 372, 1009-1018. [Google Scholar] [CrossRef] [PubMed]
[33] Berge, E., Whiteley, W., Audebert, H., De Marchis, G., Fonseca, A.C., Padiglioni, C., et al. (2021) European Stroke Organisation (ESO) Guidelines on Intravenous Thrombolysis for Acute Ischaemic Stroke. European Stroke Journal, 6, I-LXII. [Google Scholar] [CrossRef] [PubMed]
[34] Powers, W.J., Rabinstein, A.A., Ackerson, T., Adeoye, O.M., Bambakidis, N.C., Becker, K., et al. (2019) Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 50, e344-e418. [Google Scholar] [CrossRef] [PubMed]
[35] Menon, B.K., Buck, B.H., Singh, N., Deschaintre, Y., Almekhlafi, M.A., Coutts, S.B., et al. (2022) Intravenous Tenecteplase Compared with Alteplase for Acute Ischaemic Stroke in Canada (AcT): A Pragmatic, Multicentre, Open-Label, Registry-Linked, Randomised, Controlled, Non-Inferiority Trial. The Lancet, 400, 161-169. [Google Scholar] [CrossRef] [PubMed]
[36] Wang, Y., Li, S., Pan, Y., Li, H., Parsons, M.W., Campbell, B.C.V., et al. (2023) Tenecteplase versus Alteplase in Acute Ischaemic Cerebrovascular Events (TRACE-2): A Phase 3, Multicentre, Open-Label, Randomised Controlled, Non-Inferiority Trial. The Lancet, 401, 645-654. [Google Scholar] [CrossRef] [PubMed]
[37] Muir, G.F.K., Ford, I., Wardlaw, J.M., Mcconnachie, A., Greenlaw, N., Mair, G., Sprigg, N., Price, C. and Macleod, M.J. (2023) Tenectplase versus Alteplase for Acute Stroke Within 4.5H of Onset: The Second Alteplase‐Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST‐2). 15th World Stroke Congress, 10-12 October 2023, Toronto, 422-423.
[38] Alamowitch, S., Turc, G., Palaiodimou, L., Bivard, A., Cameron, A., De Marchis, G.M., et al. (2023) European Stroke Organisation (ESO) Expedited Recommendation on Tenecteplase for Acute Ischaemic Stroke. European Stroke Journal, 8, 8-54. [Google Scholar] [CrossRef] [PubMed]
[39] Noble, S. and McTavish, D. (1996) Reteplase. A Review of Its Pharmacological Properties and Clinical Efficacy in the Management of Acute Myocardial Infarction. Drugs, 52, 589-605. [Google Scholar] [CrossRef] [PubMed]
[40] Smalling, R.W. (1996) Molecular Biology of Plasminogen Activators: What Are the Clinical Implications of Drug Design? The American Journal of Cardiology, 78, 2-7. [Google Scholar] [CrossRef] [PubMed]
[41] Smalling, R.W., Bode, C., Kalbfleisch, J., Sen, S., Limbourg, P., Forycki, F., et al. (1995) More Rapid, Complete, and Stable Coronary Thrombolysis with Bolus Administration of Reteplase Compared with Alteplase Infusion in Acute Myocardial Infarction. Circulation, 91, 2725-2732. [Google Scholar] [CrossRef] [PubMed]
[42] Bode, C., Smalling, R.W., Berg, G., Burnett, C., Lorch, G., Kalbfleisch, J.M., et al. (1996) Randomized Comparison of Coronary Thrombolysis Achieved with Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients with Acute Myocardial Infarction. Circulation, 94, 891-898. [Google Scholar] [CrossRef] [PubMed]
[43] Li, S., Wang, X., Jin, A., Liu, G., Gu, H., Li, H., et al. (2023) Safety and Efficacy of Reteplase versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial. Stroke, 55, 366-375. [Google Scholar] [CrossRef] [PubMed]
[44] Li, S., Gu, H., Li, H., Wang, X., Jin, A., Guo, S., et al. (2024) Reteplase versus Alteplase for Acute Ischemic Stroke. New England Journal of Medicine, 390, 2264-2273. [Google Scholar] [CrossRef] [PubMed]
[45] Gusev, E.I., Martynov, M.Y., Nikonov, A.A., Shamalov, N.A., Semenov, M.P., Gerasimets, E.A., et al. (2021) Non-Immunogenic Recombinant Staphylokinase versus Alteplase for Patients with Acute Ischaemic Stroke 4·5 H after Symptom Onset in Russia (FRIDA): A Randomised, Open Label, Multicentre, Parallel-Group, Non-Inferiority Trial. The Lancet Neurology, 20, 721-728. [Google Scholar] [CrossRef] [PubMed]
[46] Coutts, S.B., Ankolekar, S., Appireddy, R., Arenillas, J.F., Assis, Z., Bailey, P., et al. (2024) Tenecteplase versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial. The Lancet, 403, 2597-2605. [Google Scholar] [CrossRef] [PubMed]
[47] Ghaith, H.S., Elfil, M., Gabra, M.D., Nawar, A.A., Abd-Alkhaleq, M.S., Hamam, K.M., et al. (2022) Intravenous Thrombolysis before Mechanical Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion; Should We Cross That Bridge? A Systematic Review and Meta-Analysis of 36,123 Patients. Neurological Sciences, 43, 6243-6269. [Google Scholar] [CrossRef] [PubMed]

为你推荐